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Abstract: Antibody deficiency is the most frequently encountered primary immunodeficiency 
disease (PIDD) and patients who lack the ability to make functional immunoglobulin require 
life-long replacement therapy to prevent serious bacterial infections. Human serum immuno-
globulin manufactured from pools of donated plasma can be administered intramuscularly, 
intravenously or subcutaneously. With the advent of well-tolerated preparations of intravenous 
immunoglobulin (IVIg) in the 1980s, the suboptimal painful intramuscular route of administra-
tion is no longer used. However, some patients continued to experience unacceptable adverse 
reactions to the intravenous preparations, and for others, vascular access remained problematic. 
Subcutaneously administered immunoglobulin (SCIg) provided an alternative delivery method 
to patients experiencing difficulties with IVIg. By 2006, immunoglobulin preparations designed 
exclusively for subcutaneous administration became available. They are therapeutically equivalent 
to intravenous preparations and offer patients the additional flexibility for the self-administra-
tion of their product at home. SCIg as replacement therapy for patients with primary antibody 
deficiencies is a safe and efficacious method to prevent serious bacterial infections, while 
maximizing patient satisfaction and improving quality of life.
Keywords: subcutaneous immunoglobulin, primary immunodeficiency disease, antibody 
deficiency, X-linked agammaglobulinemia, common variable immune deficiency
Background
The primary immunodeficiency diseases (PIDD) are a heterogeneous group of 
inherited disorders that affect the cells and proteins of the immune system. Defects 
in antibody production are the most common type of PIDD comprising about 60% 
of the primary immunodeficiencies encountered in practice. Prior to the advent of 
antibiotics, patients with antibody deficiency succumbed early in life to serious bac-
terial infections such as pneumonia. In 1952, the first literature report of a patient 
with recurrent sinopulmonary infections, lacking the immunoglobulin fraction in 
his serum, was published in Pediatrics by Colonel Ogden Bruton.1 He reasoned the 
patient might benefit from replacement human immunoglobulin, since the gamma 
fraction contained the antibodies known to combat bacterial infections. As a result 
of the blood banking and processing advances made during World War II, immu-
noglobulin fractionated from human plasma was available due to the efforts of 
Edwin Cohn, who employed a cold-alcohol fractionation process to separate plasma 
proteins.2 Although his work was initially focused on using the albumin fraction on 
the battlefield as a blood substitute, attention later turned to Cohn fraction II which 
contained human antibody.Therapeutics and Clinical Risk Management 2010:6 
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The syndrome described by Bruton would come to be 
known as X-linked agammaglobulinemia (XLA), a defect 
in the development of antibody producing B lymphocytes of 
boys with a mutation in the Bruton tyrosine kinase (BTK) 
gene. With adequate, regularly scheduled immunoglobulin 
replacement, using products that still employed Cohn’s 
fractionation process as one of the preparative steps, the 
first generation of boys with this disease are living into 
their third and fourth decades and beyond without end-
organ damage from chronic, recurrent bacterial infections. 
Lifelong antibody replacement therapy is also indicated 
for common variable immune deficiency (CVID), a defect 
of antibody production often with later onset. Many other 
primary immune defects have a component of antibody 
deficiency and also benefit from replacement with human 
immunoglobulin.
The evolution of immunoglobulin 
replacement therapy
Following Bruton’s initial description of the beneficial 
effects of antibody replacement in a patient with severe 
deficiency in immunoglobulin production, intramuscular 
dosing became the primary route of administration. In the 
mid 1950s weekly intramuscular immunoglobulin (IMIg) 
injections became the standard of care, however, they were 
poorly tolerated by most patients, particularly children, due 
to the discomfort that accompanied them. The volume of 
product that could be given was limited, and serum IgG levels 
rarely approached physiologic concentrations. Compliance 
with intramuscular injections was understandably poor 
in many patients. Occasionally, some of the IMIg would 
inadvertently enter a vein, resulting in a severe anaphylactic 
reaction.
In an attempt to optimize the response to therapy and 
to decrease discomfort, some practitioners used whole 
plasma infusions intravenously. During the 1960s attempts 
were made to formulate a usable intravenous preparation of 
immunoglobulin. Early attempts were fraught with problems 
related to the aggregation of IgG molecules during prepara-
tion and storage. These aggregates are thought to activate 
complement when infused intravenously, producing severe 
systemic side effects such as hypotension, angioedema, rigors 
and fever. The first immunoglobulin products introduced 
for widespread intravenous use were Gamimune® (Cutter 
Biologicals) and Sandoglobulin® (Sandoz Pharmaceuticals, 
now Novartis) in the early 1980s. With the addition of sugars, 
and subsequently amino acids as stabilizers to prevent aggre-
gation of IgG molecules, the systemic side effects associated 
with IVIg have been markedly reduced in subsequent gen-
erations of IVIg products. The currently available products, 
summarized in Table 1, have mild systemic reaction rates of 
2% to 6%.3 While most reactions are related to the rate of 
infusion, patients are also more likely to experience reactions 
to IVIg during the first and second infusion, after a significant 
interruption in therapy, or if they have an active infection at 
the time of their infusion.
Table  Characteristics of immune globulin products currently available in the United States
Manufacturer IgG conc. IgA conc.  
(mg/mL)
Excipients Osmolality  
(m0sm/kg)
Viral safety
Products intended for intravenous use (liquid preparations)
Flebogamma® DiF Grifols 5% 50 50 mg/mL D-sorbitol 240–370 Chromatography  
↓ pH/↑ temp treatment, S/D, NF
Gammagard Liq. Baxter 10% 37 250 mM glycine 240–300 Chromatography  
↓ pH/↑ temp treatment, S/D, NF
Gamunex® Talecris 10% 46 200 mM glycine 258 Chromatography  
↓ pH incubation
Octagam® Octapharma 5% 100 10% maltose 310–380 Chromatography S/D
Privigen® CSL-Behring 10% 25 250 mM L-proline 320 Chromatography  
↓ pH incubation, NF
Products intended for subcutaneous use
vivaglobin® CSL-Behring 16% 1700 3 mg/mL NaCl  
250 mM glycine
445 Chromatography  
↑ Temp treatment
Products intended for intramuscular use
GamaSTAN® Talecris 16% NL 300 mM glycine NL S/D
Abbreviations: NF, nanofiltration; UF, ultrafiltration; S/D, solvent/detergent; NL, not listed.Therapeutics and Clinical Risk Management 2010:6 
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Other significant though less frequent side effects 
reported with IVIg therapy include renal failure, aseptic 
meningitis and thrombosis. Episodes of renal failure with 
sucrose containing IVIg products prompted an FDA warn-
ing related to the use of sugar containing product with high 
osmolality in patients with pre-existing renal insufficiency. 
These side effects are also related to the hydration status 
of the patient and to higher doses of IVIg.4 Finally, there 
was recognition in the late 1980s and early 1990s, that 
the accepted preparative approaches that included a single 
viral inactivation step were not adequate to prevent trans-
mission of, at that time uncharacterized virus, Hepatitis C. 
Subsequent immunoglobulin products have been manufac-
tured using at least two different viral inactivation proce-
dures, and some newer generation products attempt to screen 
out prions as well.
Subcutaneous therapy
The first report of subcutaneous immunoglobulin therapy 
(SCIg) using an available intramuscular preparation was 
published in 1980 by Berger and colleagues. Three adult 
patients with inadequate infection control and poor com-
pliance with IMIg or intolerance of plasma replacement 
infusions were given 5–15 mL of immunoglobulin by slow 
subcutaneous infusion (1–2 mL/h) several times a week.5 
Patients were able to maintain their serum IgG concentra-
tions at 500 mg/dL or greater, and had marked improvement 
in their quality of life. One patient was even able to begin to 
work full time. Soon after this report, IVIg therapy became 
readily available and clinicians embraced the intravenous 
method of administration. Higher levels of serum IgG were 
easily attainable and the clinical benefit was realized with a 
substantial decrease in serious bacterial infections, recur-
rent pneumonias, and chronic bronchiectasis.6,7 Although 
several investigators throughout the 1980s continued to 
publish articles outlining the benefits of subcutaneous 
infusions using 16% intramuscular preparations of immu-
noglobulin, the time required for these slow infusions, and 
the ready availability of the new IVIg products made the 
subcutaneous route of administration less desirable for 
most patients.
Limitations for some patients using the intravenous 
route soon became evident. By 1991 a letter to the journal 
Lancet reported the use of an implantable intravenous device 
(Port-a-cath®) in an adult patient who no longer had periph-
eral venous access for IVIg.8 However; many clinicians had 
less success with the use of indwelling intravenous catheters in 
immunodeficient patients requiring lifelong immunoglobulin 
therapy and the increased risk of serious bacterial infections 
in this population made the approach less appealing. Infants 
were a particularly difficult patient population when it came 
to maintaining stable venous access.
As clinicians gained more experience with the early 
IVIg products during the 1980s and early 1990s, it became 
apparent that adverse reactions such as headache, fever, 
chills, myalgias, fatigue, and nausea were problematic for a 
subgroup of patients, even with slow intravenous infusions. 
The published prevalence of these reactions varied widely 
(at times reported as high as 27%), prompting the need for 
premedication with acetaminophen, steroids, and antihis-
tamines in some individuals receiving IVIg.9 In an attempt 
to minimize these systemic adverse events, and to make 
subcutaneous infusions more appealing to patients in terms 
of time commitment, Gardulf and colleagues reported the 
delivery of a 16% intramuscular immunoglobulin prepara-
tion widely available in Sweden, using a rapid subcutane-
ous infusion technique.10 The Swedish group administered 
over 3000 subcutaneous infusions to 25 adult patients, 15 
of whom had reported systemic reactions to IMIg or IVIg, 
using subcutaneous infusion rates of 17–20 mL/h. Although 
the groups were small, the rates of mild systemic reactions 
such as fatigue, dizziness, chills, or nausea were 0.93% for 
subcutaneous infusions, 46.3% for intravenous infusions, 
and 22.2% for intramuscular administration. Eight patients 
receiving IMIg reported 20 severe systemic reactions (1.1% 
of infusions), with one experiencing circulatory collapse. 
There were no severe reactions in the group receiving 
subcutaneous infusions, in fact almost two thirds of these 
infusions were given outside the hospital setting, at home 
or at work. Virtually all patients receiving subcutaneous 
therapy reported local site reactions of swelling, erythema, 
tenderness and induration, but in 67% of the patients, these 
reactions lasted less than 24 hours. There were no severe 
systemic reactions noted with subcutaneous administration 
of the intramuscular immunoglobulin preparation, even in 
those patients who had previously reported severe reaction 
with the intramuscular route.
Gardulf’s group also attempted “express” subcutaneous 
infusions, allowing patients who tolerated the 20 mL/hr rapid 
infusion rate to increase it to 40 mL/h.11 Patients rated their 
perceptions of local tissue reactions but the actual degree of 
swelling or erythema was not measured. The percentages of 
patients reporting local tissue reactions using a 20 mL/h rate 
versus a 40 mL/h rate was no different (50% for rapid and 
46% for express infusion rates). Overall, 24% of those report-
ing local site reactions reported a more intense reaction when Therapeutics and Clinical Risk Management 2010:6 
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using the express rate, while 66% felt there was no change. 
Ten percent of patients felt the reaction was less intense.
Rapid subcutaneous infusions were soon evaluated in 
children and found to be feasible.12–14 In the United States, 
where a concentrated (16% or greater) mercury free, intra-
muscular product was not as readily available as in Europe, 
Stiehm and colleagues reported that the available intravenous 
products ranging in concentration from 10%–12%, could be 
given safely via the subcutaneous route.15 In the mid to later 
part of the 1990s, larger scale European prospective stud-
ies began to evaluate the safety, efficacy and cost of using 
an available 16% intramuscular preparation compared to 
intravenous immunoglobulin. It was nearly 10 years, how-
ever, before the first human trials were done to evaluate an 
immunoglobulin preparation specifically formulated for 
subcutaneous use.
Pharmacokinetics of SCIg
The pharmokinetics of exogenous immunoglobulin varies 
by route of administration. Intravenous infusions, given in 
the customary doses of 300–400 mg/kg every 3–4 weeks, 
produces peak serum IgG levels within 15 minutes of 
completing the infusion, and takes 48–72 hours to become 
distributed from the intravascular compartment to the total 
extracellular fluid. Initially, the intravascular concentration 
of IgG increases by 200–300 mg/dL for every 100 mg/kg 
of IVIg given and with redistribution into the extracellular 
compartment, serum levels fall by approximately 50%.16 
After reequilibration, IgG is catabolized, with a half-life 
of approximately 22 days. The half-life of IgG can be up 
to 30 days in patients with hypo- or agammaglobulinemia. 
In contrast, subcutaneous administration results in a more 
stable and consistent serum IgG concentration, although 
therapeutic plasma levels are not reached as quickly.17 Early 
studies demonstrated that maximal plasma concentrations 
of IgG are not reached until 4–6 days after intramuscular or 
subcutaneous administration.18 At an immunoglobulin dose 
of 100 mg/kg/week given subcutaneously, steady state is 
achieved after six months of therapy; however, if the same 
dose is administered daily for five consecutive days, steady 
state can be achieved in a week.19 For patients transitioning 
from IVIg to SCIg, subcutaneous infusions given within the 
first week of receiving the last IV dose allows the IgG level 
to remain therapeutic.
These pharmacokinetic differences are reflected in the 
magnitude of difference observed in peak and trough levels 
between intravenous versus subcutaneous dosing. In one 
comparative study, patients receiving intravenous therapy 
every three weeks had peak and trough levels that spanned 
a range of 900 mg/dL, while the range seen with weekly 
subcutaneous administration was less than 100 mg/dL.17 
Thus, while trough determinations are important guides 
for assessing the adequacy of IVIg replacement therapy, 
IgG levels can be assessed at any time after steady state is 
reached to determine the adequacy of subcutaneous replace-
ment therapy.
Systemic side effects of immunoglobulin treatment have 
been associated with the significant fluctuations between 
peak and trough levels with IV infusions. A patient survey 
in 2008 by the Immune Deficiency Foundation reported that 
68% of respondents noted fatigue and increased susceptibil-
ity to infections at the time of their trough nadir just prior to 
their next IVIg infusion.20 Clinicians have also attempted to 
correlate infusion related side effects such as headache and 
back pain to high peak serum IgG levels.21 In contrast, a lower 
systemic side effect profile has been consistently observed 
throughout many reports of subcutaneous replacement 
therapy, most likely related to the more stable physiologic 
IgG levels achieved.22
The bioavailability of subcutaneous immunoglobulin has 
not been clearly determined, and this prompted discussion 
of appropriate dosing when the first North American clini-
cal trial to evaluate a new SCIg (Vivaglobin®) was designed. 
The European trial evaluating the same product used doses 
comparable to the standard IVIg replacement dose, adjusted 
to provide a comparable weekly amount. (An IVIg dose of 
300 mg/kg every three weeks translated to 100 mg/kg per 
week of SCIg). For the North American trial, the Food and 
Drug Administration (FDA) required a dose determined by 
a time-averaged area under the curve that was comparable 
to that seen with IVIg. Based on pharmacokinetics, patients 
in this trial received an average of 1.37 times the IV dose 
when converting to subcutaneous product. Mean “trough” 
levels rose by 39% (from 786 mg/dL while on IVIg to 
1040 mg/dL while on SCIg) with conversion from IV to 
subcutaneous immunoglobulin.23 Another European trial 
published six years before the Vivaglobin® study, evaluating 
the safety and efficacy of IVIg versus an intramuscular 
immunoglobulin product given subcutaneously, noted similar 
serum IgG levels in their patients without an increased dose 
of immunoglobulin for the subcutaneous arm of the study. 
Although it was not an endpoint in their study, and only half 
of the patients had IgG trough levels compared during the first 
six months of this two-year study, the authors reported median 
IgG trough levels of 780–840 mg/dL in patients receiving 
IVIg and 800–910 mg/dL in patients receiving subcutaneous Therapeutics and Clinical Risk Management 2010:6 
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infusions using comparable doses of each product.24 The 
results of the European Vivaglobin® trial confirmed the 
suggestion by the earlier European trial and no drop in IgG 
level was seen using the same cumulative monthly dose for 
subcutaneous therapy that was given for IV therapy. A sample 
calculation for directly converting a patient from IVIg to SCIg 
at the same monthly dose is shown in Table 2.
Efficacy of subcutaneous 
immunoglobulin
Prior to the prospective North American and European clinical 
trials published in 2006 confirming the safety and efficacy 
of a new 16% product (Vivaglobin®) designed only for sub-
cutaneous use, a trial by Chapel and colleagues compared 
the efficacy and safety of subcutaneous Gammaglobulin 
(a 16% intramuscular preparation) to intravenous Endobulin 
(a 5% intravenous preparation). This was a randomized cross-
over trial with a primary endpoint of number and severity of 
infections during the two-year trial period. Thirty patients 
were enrolled and randomized with the finding that there 
was no difference in the efficacy or adverse reaction rate of 
the two therapies. Mean infection scores for moderate and 
major infections were the same for both treatments.24 This 
trial excluded patients with high levels of anti-IgA antibodies 
or a history of severe adverse reactions to a blood product 
within the last two years, which possibly affected the adverse 
reaction data. In addition, local site reactions were included 
with mild systemic reactions in the evaluation of adverse 
reactions, while most investigators differentiate between 
systemic reactions and local infusion site reactions of  swelling, 
pain or erythema. The prospective, longitudinal European 
Vivaglobin® trial evaluated 60 patients with a variety of PIDD, 
including IgG subclass deficiency, although the majority 
carried diagnoses of CVID or XLA. Eligible patients could 
be on subcutaneous immunoglobulin using an intramuscular 
preparation or IVIg as long as they had been on therapy for 
at least six months with defined, stable IgG trough levels. 
No increase in dose was given when transitioning from IVIg 
therapy. Mean serum IgG trough levels while on Vivaglobin® 
were analyzed separately for children and adults; however, 
both groups demonstrated noninferiority when compared 
with the IVIg preparation. One bacterial pneumonia was 
reported and the annual rate of serious bacterial infections 
in the group receiving Vivaglobin® was 0.04 per patient per 
year.25 The North American Vivaglobin® trial, also published 
in 2006, required a diagnosis of either CVID or XLA for 
enrollment. Patients with normal levels of serum IgG who 
lacked evidence of functional antibodies or patients with 
IgG subclass deficiency were not included in this trial. All 
68 enrolled patients were on IVIg at the start of the study 
which included a baseline observation of 3–4 weeks while 
the patients continued to receive IVIg, followed by a 12-week 
wash in/wash out period after transitioning to an adjusted, 
higher dose of Vivaglobin® (1.37 × IVIg dose). The subse-
quent efficacy phase lasted 52 weeks and the primary end-
point measured was the number of serious bacterial infections 
Step Sample calculation
1 Calculation of weekly IVIg dose:
___________ ÷ 4 =  ___________ 
Grams/month Grams/week
A 50 kg patient receives 
20 grams (400 mg/kg) of IVIG 
every four weeks. 
Weekly dose = 20 ÷ 4 = 5 grams/week. 
2 Calculation of weekly SCIg volume (16% preparation∗∗): 
___________ ÷ 0.16 (Grams/mL)   = ____________ 
Grams/week
5 grams/week needed 
5 ÷ 0.16 = 31.25 mL/week 
3 Infuse into 1 or more sites according to these rules:
• No more than 25 mL/site in adults or 15 mL/site in children. 
• Infusion rate of no more than 1mL/1 minute.
Based on available Vivaglobin®
vial sizes of 3, 10, and 20 mL∗∗, 
round dose up to 33 mL/week. 
Infuse in 2 sites once weekly. 
Calculations
mL/week
Notes: **Prescribe according to available vial sizes. 16%    vivaglobin® is available in single use vials of 3 mL (0.48 g), 10 mL (1.6 g) and 20 mL (3.2 g).
Table  Sample calculation process for converting from ivig to SCigTherapeutics and Clinical Risk Management 2010:6 
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such as pneumonia, meningitis, sepsis, osteomyelitis or 
visceral abscess during this period. The annual rate of serious 
bacterial infections during the efficacy phase was the same 
as in the European trial, and the annual rate of any type of 
infection was 4.43 per patient per year.23 Both trials concluded 
that Vivaglobin® administered subcutaneously was an effec-
tive alternative to IVIg in patients with PIDD.
Safety of subcutaneous 
immunoglobulin
Prior to the development of an immunoglobulin product 
intended only for subcutaneous use, intramuscular or 
intravenous immunoglobulin preparations were given via the 
subcutaneous route chiefly because of its lower side effect 
profile. A multiparameter comparison of IVIg and SCIg 
is provided in Table 3. From 1991 to 2003, several studies 
found a low systemic reaction rate ranging from 0.3% to 
3.3%, while local tissue reactions were reported in 2.1% to 
20% of patients.26 The first Scandinavian retrospective study 
published in 1995 evaluating over 33,000 subcutaneous 
infusions in patients with PIDD, reported 100 mild and six 
moderate systemic reactions, and no severe or anaphylac-
toid reactions.27 Up to 87% of patients reported local tissue 
reactions at least once, and this was inversely correlated 
with their body mass index. Leaner patients were more 
likely to perceive inconvenience based on local reactions of 
swelling, tenderness and induration. There were no reported 
differences with slow versus rapid subcutaneous infusion, 
other than more pronounced itching associated with rapid 
infusions. No infusion site abscesses or skin infections 
were noted. The prospective European Vivaglobin® trial 
reported systemic adverse reactions in 1% of infusions.25 
These consisted chiefly of fever, dizziness, malaise, and 
nongeneralized skin reactions. There was one report of 
wheezing that subsided after the infusion was stopped. 
However, this patient was able to resume the subcutaneous 
infusion with no further adverse event. One patient developed 
hypotension 10 minutes after insertion of the subcutaneous 
needle for his first infusion, and with the infusion of 0.5 mL 
of immunoglobulin. This reaction was determined to be a 
vasovagal response. Transient localized tissue reactions were 
reported in 28% of infusions. Patients transitioning from 
IVIg to Vivaglobin® were most affected, although these local 
reactions decreased over time.
In the prospective North American Vivaglobin® trial, the 
most frequently reported treatment related adverse events 
were headache, nausea, rash, weakness and gastrointestinal 
symptoms. While the rate of infusion related headache was 
1.6%, all other frequently reported events each occurred at 
a rate of less than 1%.23 Transient localized tissue reactions 
were reported in 49% of infusions. One possible explanation 
for the difference in reported localized reactions between the 
two trials is that all patients in the US study transitioned from 
IVIg to the subcutaneous preparation unlike the European 
study where some patients were already on subcutaneous 
therapy with another product at the start of the trial.
A recent Italian study suggests there may be a small 
subset of patients with CVID who deserve special 
consideration when transitioning from IVIg to subcuta-
neous therapy because of unacceptable adverse events. 
Among the 262 patients diagnosed with CVID from 1999 
to 2007, and enrolled in a prospective study by the Italian 
Primary Immunodeficiency Network, 13 patients devel-
oped severe adverse reactions to IVIg (hypotension, chills 
and fever, headache, nausea, and angioedema) that were 
not completely prevented by premedication or changing 
Table  Comparison of SCig and ivig
SCIg IVIg
Pharmacokinetics Consistent serum igG levels wide difference in serum igG level between peak 
and trough
Efficacy Two prospective trials demonstrate 
noninferiority compared to ivig
Long clinical experience demonstrating efficacy
Systemic side effects infrequent Common
Infusion site reactions Common infrequent
Factors contributing 
to total cost
Self administered at home. US trials of vivaglobin 
suggested using higher dose (1.37x) than ivig
Typically administered in an infusion center with 
nursing support.
Patient satisfaction Offers flexibility of infusion frequency, site, etc. 
Multiple studies confirm enhanced quality of life 
in PiDD patients.
Often a better option for patients who have difficulty 
with needles and/or self-injection. Preferable in 
patients who have difficulty with compliance.
Abbreviations: Ig, immunoglobulin, IVIg, intravenous immunoglobulin, SCIg, subcutaneous immunoglobulin; PIDD, primary immunodeficiency disease.Therapeutics and Clinical Risk Management 2010:6 
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to different commercial preparations of IVIg. Only one of 
these patients had detectable anti-IgA antibodies, which 
have been proposed as a possible risk factor for severe infu-
sion reactions. All thirteen patients were eventually able to 
transition to a commercially available subcutaneous product, 
but two patients experienced adverse reactions with SCIg: 
one developed hypotension and angioedema with the first 
infusion of Vivaglobin® given after IVIg infusions had been 
discontinued for seven years. Subcutaneous infusions were 
resumed one month later and tolerated well using an alternate 
subcutaneous product (Subcuvia, Baxter). The second patient 
developed hypotension, chills and fever after nine months 
of tolerating subcutaneous infusions of Vivaglobin®. His 
subcutaneous therapy was continued, but at a lower dose, and 
he was eventually able to gradually increase his dose back to 
therapeutic levels.28 The mechanisms of these single episodes 
of adverse events are unknown. Importantly, both patients 
eventually tolerated subcutaneous immunoglobulin infusions 
demonstrating that SCIg replacement therapy provides a safe 
alternative that is well tolerated.
Finally, there are special groups of patients, often 
excluded from clinical trials, who have safely received sub-
cutaneous immunoglobulin therapy. Patients with anti-IgA 
antibodies, intolerant of low-IgA IVIg have successfully 
been transitioned to subcutaneous therapy.20,29 Young chil-
dren and pregnant women with PIDD have safely received 
subcutaneous infusions of immunoglobulin.30,31 And while 
little data exists on the use of subcutaneous immunoglobulin 
therapy in patients with significant thrombocytopenia, anti-
coagulant use or bleeding disorders, there is a report of the 
safe use of subcutaneous therapy in a child with CVID and 
von Willebrand disease.32
Comparative costs 
of immunoglobulin therapy
There is no systematic body of data with which to evaluate the 
costs of intravenous versus subcutaneous immunoglobulin 
therapy and the implications for health care policy. Since 
health care economics vary markedly among countries, an 
analysis of this subject would have to be nation-specific.
Swedish estimates in 1995 comparing the cost of sub-
cutaneous versus intravenous immunoglobulin therapy 
calculated a reduction of about $10,000 per patient per 
year using the subcutaneous route. This estimate was based 
on US dollars at 1993 prices.27 At the time, the cost of the 
intramuscular product used for subcutaneous therapy in 
Sweden was less than the cost of the intravenous product. 
However, all cost estimates agree that the immunoglobulin 
product itself constitutes most of the treatment cost, and that 
home therapy is preferable to institutional infusion therapy, 
whether the intravenous or subcutaneous route is used. 
The subcutaneous route greatly facilitates home therapy. 
Berger estimated a savings in 2004 of $2000 to $5000 per 
patient per year by avoiding facility costs associated with 
infusions.26
Radinsky and Bonagura published a price comparison 
of associated costs, exclusive of product cost, in New York 
in 2003 for home subcutaneous versus intravenous immu-
noglobulin therapy using a home care company. Intravenous 
therapy cost 3.4 to 6.5 times more in nursing care and 
equipment compared to subcutaneous therapy.33 This was 
in line with the Swedish finding ten years earlier that home 
intravenous therapy was three to four times more expensive 
than home subcutaneous infusions.27A 2005 cost analysis 
in Germany estimated that converting 60% of patients 
on IVIg to subcutaneous therapy would realize a savings 
of  €17 to 77 million per year.34
No study has taken into account the economic cost of 
missed hours from work or school, loss of productivity 
from untreated PIDD, additional costs of antibiotics or acute 
medical care, or the effect of the pricing structure of immu-
noglobulin on health care macroeconomics.
Patient satisfaction
Although the initial Vivaglobin® trials called for a weekly 
infusion of subcutaneous immunoglobulin, experienced 
clinicians have discovered that patients do well when they 
are able to determine their own home infusion schedules. 
Subcutaneous therapy gives them a large degree of freedom 
to do this. The volume of immunoglobulin administered per 
site can range from 5–30 mL, with most clinicians preferring 
10–20 mL per site when using a pump. This can be adjusted 
according to the body habitus, age, and preference of the 
patient. Injection locations commonly used include the abdo-
men, lateral thighs, buttocks and upper arms. One or multiple 
needle sites per infusion can be used. Tubing sets are now 
available that make it possible for patients to infuse into four 
sites simultaneously. The time that it takes to infuse generally 
varies between one to two hours, but some patients prefer a 
longer infusion while they are sleeping or performing other 
activities. Other patients prefer to utilize a slow push method 
(1 mL/minute) to infuse a smaller amount (5–10 mL/site) 
of immunoglobulin daily from a hand held syringe. The 
required weekly dose can be divided in many fashions, as 
long as the prescribed weekly amount of immunoglobulin is 
given. The equipment needed is simple: some patients use a Therapeutics and Clinical Risk Management 2010:6 
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23 gauge butterfly needle while others prefer a subcutaneous 
needle that can be loaded into a penlike selfinjector. If an 
infusion pump is used, only a simple pump is needed – in 
fact, patients can become discouraged if the pump supplied 
to them is too complex.
The first quality of life survey related to subcutane-
ous administration of immunoglobulin in patients with 
PIDD was performed in Sweden and published in 1993. 
Gardulf’s report on the “life situations” of people with 
antibody deficiency provides a stark assessment of untreated 
patients. She used validated tests to assess patient’s percep-
tions of infections, social interaction, and self-rated health 
status while comparing antibody deficient patients prior 
to starting immunoglobulin replacement therapy to other 
defined comparison groups. The eight reference groups 
included cohorts of patients with other chronic diseases, 
as well as healthy individuals. The PIDD group that did 
not receive immunoglobulin treatment prior to entering the 
study (n = 10) rated their health status similar to patients in 
renal failure or with rheumatoid arthritis. After 18 months of 
weekly subcutaneous infusions of IgG, the patients (n = 25) 
reported increased health-related function and improved 
self-rated health.35 From 2004 to 2007 a number of stud-
ies outlined the improvement in health-related quality of 
life for patients receiving subcutaneous immunoglobulin 
therapy.21,36–39 While some of the perceived improvement 
may be due to the ability to receive therapy easily at home 
and avoid repeated visits to health care facilities, all studies 
show that subcutaneous therapy improves a patient’s and 
family’s sense of independence and self mastery of their 
situation. Flexibility of the treatment regimen helps patients 
cope with this life long therapy.
Clinicians stress that an involved and motivated patient 
is the ideal candidate for subcutaneous therapy, and some 
physicians have noted falling IgG levels on home subcu-
taneous therapy due to waning patient compliance.40 Some 
parents may feel overwhelmed having to perform regular 
subcutaneous injections for their young child.13 Not all 
people prefer subcutaneous therapy when given a choice. 
The patients in Chapel’s cross-over study preferred IVIg to 
subcutaneous therapy, 53%–33%. The remainder had no 
preference.24 The most frequent reason for dissatisfaction, 
even in patients who preferred subcutaneous therapy, was 
the higher infusion frequency.14 Still others dislike the local 
site reactions, which tend to improve over time. Several of 
the patients who dropped out of the prospective Vivaglobin® 
trials did so because of dissatisfaction with local reactions.23,25 
The medical community is trying to address the concerns 
related to frequency of infusion. A recent publication 
reported stable serum IgG levels with every second week 
subcutaneous administration.41 A trial of locally injected 
human recombinant hyaluronidase followed by subcutaneous 
infusion of a full month’s volume of immunoglobulin into the 
same site is being planned in an attempt to stretch infusions 
to a monthly schedule.
Conclusion
Subcutaneous immunoglobulin therapy is a safe and 
effective choice for IgG replacement in patients with PIDD. 
Two prospective studies demonstrated that it has equivalent 
efficacy to IVIg in preventing serious bacterial infections 
in patients with antibody deficiency. The systemic side 
effect profile is low, and while local tissue reactions are 
frequent they are often mild and tend to improve over 
time. Pharmacokinetic studies reveal a more physiologic 
profile, without large variations in peak and trough levels 
of serum IgG. A number of studies document improved 
health-related quality of life in patients on home subcu-
taneous immunoglobulin therapy. Since the treatment is 
given at home, using simple supplies and no nursing care, 
the cost is decreased although most of the cost related to 
immunoglobulin replacement therapy is due to the cost of 
the product itself.
Patients reporting less satisfaction with subcutaneous 
therapy cite the frequency of injections and local site 
reactions as the primary reasons. However, the method of 
delivery, volume injected, rapidity of infusion, number of 
sites, and number of infusions per week can be adjusted to 
meet specific patient needs as long as the prescribed weekly 
amount of immunoglobulin is administered. Patients that 
benefit from this form of therapy include those with poor 
venous access, those experiencing systemic adverse reac-
tions to IVIg, and patients with anti-IgA antibodies thought 
to be a risk factor for systemic reactions. In addition, some 
clinicians have noted more stable IgG levels in patients with 
PIDD and protein-losing enteropathy. Subcutaneous therapy 
has also been utilized in patient groups often excluded in 
conventional clinical trials, including young children and 
pregnant women.
The increasing use of the subcutaneous infusion 
method in patients with PIDD has brought the story of 
immunoglobulin replacement therapy full circle, since 
that was the initial method of infusion Bruton utilized in 
the fifties to treat his first agammaglobulinemic patient.1 
This treatment has demonstrated efficacy in improving the 
quality of life and health in a group of patients with an Therapeutics and Clinical Risk Management 2010:6 
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otherwise life-threatening chronic disease. With current 
efforts to improve the effectiveness of health care delivery, 
it could become a model of how to rationally modify a 
costly therapy for a chronic illness in order to decrease 
cost and enhance health-related quality of life while 
maintaining efficacy.
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